当前位置:科学网首页 > 小柯机器人 >详情
单次接种核苷修饰的mRNA疫苗可引起强烈新冠病毒免疫反应
作者:小柯机器人 发布时间:2020/8/2 11:54:29

美国宾夕法尼亚大学Norbert Pardi研究团队通过单次接种核苷修饰的mRNA疫苗,在小鼠中引发针对SARS-CoV-2的强烈细胞和体液免疫反应。这一研究成果于2020年7月30日在线发表在《免疫》上。

研究人员提供了对脂质纳米颗粒包裹的、核苷修饰的mRNA(mRNA-LNP)疫苗(编码全长SARS-CoV-2突刺蛋白或突刺受体结合域)在小鼠中免疫原性的详细评估。研究人员证明这些疫苗的单剂量可诱导强烈的1型CD4+和CD8+T细胞反应,以及长期的血浆和记忆B细胞反应。

此外,研究人员检测到强大且持续的中和抗体反应,而核苷修饰的mRNA疫苗引发的抗体在体外并未表现出抗体依赖性的感染增强作用。这些发现表明,核苷修饰的mRNA-LNP疫苗平台可以诱导强大的免疫反应,并且是对抗COVID-19的有望候选。

SARS-CoV-2感染已成为严重的全球性大流行。由于病毒的高传播性以及与COVID-19相关的高发病率和死亡率,因此开发有效和安全的疫苗是研究的重中之重。

附:英文原文

Title: A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice

Author: Dorottya Laczkó, Michael J. Hogan, Sushila A. Toulmin, Philip Hicks, Katlyn Lederer, Brian T. Gaudette, Diana Castao, Fatima Amanat, Hiromi Muramatsu, Thomas H. Oguin, Amrita Ojha, Lizhou Zhang, Zekun Mu, Robert Parks, Tomaz B. Manzoni, Brianne Roper, Shirin Strohmeier, István Tombácz, Leslee Arwood, Raffael Nachbagauer, Katalin Karikó, Jack Greenhouse, Laurent Pessaint, Maciel Porto, Tammy Putman-Taylor, Amanda Strasbaugh, Tracey-Ann Campbell, Paulo J.C. Lin, Ying K. Tam, Gregory D. Sempowski, Michael Farzan, Hyeryun Choe, Kevin O. Saunders, Barton F. Haynes, Hanne Andersen, Laurence C. Eisenlohr, Drew Weissman, Florian Krammer, Paul Bates, David Allman, Michela Locci, Norbert Pardi

Issue&Volume: 2020-07-30

Abstract: SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4+ and CD8+ T cell responses, as well as long-lived plasma and memory B cell responses. Additionally, we detect robust and sustained neutralizing antibody responses and the antibodies elicited by nucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro. Our findings suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.

DOI: 10.1016/j.immuni.2020.07.019

Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30326-5

期刊信息

Immunity:《免疫》,创刊于1994年。隶属于细胞出版社,最新if:21.522
官方网址:https://www.cell.com/immunity/home
投稿链接:https://www.editorialmanager.com/immunity/default.aspx